MX367908B - Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. - Google Patents
Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.Info
- Publication number
- MX367908B MX367908B MX2017001930A MX2017001930A MX367908B MX 367908 B MX367908 B MX 367908B MX 2017001930 A MX2017001930 A MX 2017001930A MX 2017001930 A MX2017001930 A MX 2017001930A MX 367908 B MX367908 B MX 367908B
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- synthetic intermediates
- tetrahydroquinoline derivatives
- derivatives
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un proceso para la preparación de intermediarios sintéticos que se pueden usar en la preparación de derivados de tetrahidroquinolina, cuyos derivados tienen una actividad inhibidora contra proteína de transferencia de colesterilo (CETP), muestran efectos de incrementar el nivel de colesterol HDL y disminuir el nivel de colesterol LDL, y se pueden usar para el tratamiento y/o prevención de enfermedades tales como enfermedades arterioscleróticas, hiperlipidemia, dislipidemia y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 | ||
| PCT/NL2015/050555 WO2016024858A1 (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001930A MX2017001930A (es) | 2018-03-01 |
| MX367908B true MX367908B (es) | 2019-09-11 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001930A MX367908B (es) | 2014-08-12 | 2015-07-29 | Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (es) |
| EP (2) | EP4083022A1 (es) |
| JP (1) | JP6670310B2 (es) |
| KR (1) | KR102572626B1 (es) |
| CN (1) | CN107108558B (es) |
| AR (1) | AR101509A1 (es) |
| AU (1) | AU2015302407B2 (es) |
| BR (1) | BR112017002873B1 (es) |
| CA (1) | CA2958040C (es) |
| CL (1) | CL2017000367A1 (es) |
| DK (1) | DK3180314T3 (es) |
| EA (1) | EA034357B1 (es) |
| ES (1) | ES2926775T3 (es) |
| HR (1) | HRP20221061T1 (es) |
| HU (1) | HUE059947T2 (es) |
| IL (1) | IL250525B (es) |
| LT (1) | LT3180314T (es) |
| MA (1) | MA40378B1 (es) |
| MX (1) | MX367908B (es) |
| PL (1) | PL3180314T3 (es) |
| PT (1) | PT3180314T (es) |
| RS (1) | RS63575B1 (es) |
| SG (1) | SG11201701077XA (es) |
| SI (1) | SI3180314T1 (es) |
| TW (1) | TWI691490B (es) |
| WO (1) | WO2016024858A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023017999A2 (pt) | 2021-03-05 | 2023-11-14 | Newamsterdam Pharma B V | Obicetrapibe para tratamento de demências |
| EP4376832A1 (en) | 2021-07-26 | 2024-06-05 | NewAmsterdam Pharma B.V. | Treatment of his hyporesponders |
| WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| WO2024009144A1 (en) | 2022-07-05 | 2024-01-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2024042061A1 (en) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| RU2265010C2 (ru) * | 2001-04-30 | 2005-11-27 | Пфайзер Продактс Инк. | Промежуточные соединения для ингибиторов cetp и способы их получения |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
-
2015
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active IP Right Grant
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en active Application Filing
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es unknown
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3389725A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| EP3261440A4 (en) | Methods and compositions for treating genetic eye diseases | |
| WO2015153800A3 (en) | Compositions for modulating sod-1 expression | |
| EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | |
| EP3119913A4 (en) | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| EP3377090A4 (en) | Methods for treatment of bile acid-related disorders | |
| EP3503906A4 (en) | METHOD FOR TREATING BILIC ACID DISEASES | |
| EP3096617A4 (en) | Compositions and methods for treating ocular diseases | |
| EP3157531A4 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| MX367908B (es) | Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. | |
| EP3182979A4 (en) | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss | |
| EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
| EP3131556A4 (en) | Methods and compositions for treatment of copd diseases | |
| EP3263119A4 (en) | Composition including extracellular vesicles derived from bacteria of bacillus sp. for treating pregnancy-associated diseases | |
| EP3348273B8 (en) | Compositions based on xyloglucan and proteins for the treatment of intestinal disorders | |
| EP3192875A4 (en) | Sustained-release pharmaceutical composition for treating and preventing ophthalmic diseases | |
| EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
| EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
| EP3326638A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IL-6-MEDIATED DISEASES WITH ROSA RUGOSA | |
| EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
| EP3115117A4 (en) | Plant and process for the treatment of the subproducts derived from the extraction of virgin olive oil | |
| EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| EP3501524A4 (en) | USE OF PHYTOSPHINGOSINE-1-PHOSPHATE OR A DERIVATIVE THEREOF AS AN IMMUNE ACTIVATOR OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEMENTIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |